Dr. Arend on Niraparib With Bevacizumab in Ovarian Cancer

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian CancerПодробнее

Dr. Arend on FDA Approval of Frontline Bevacizumab in Ovarian CancerПодробнее

The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее

Dr. Mirza Discusses Niraparib Dose Modifications for Ovarian Cancer Patients With Low Body WeightПодробнее

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Combination Therapy With Niraparib and Bevacizumab for Ovarian CancerПодробнее

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian CancerПодробнее

Dr. Mirza on Niraparib Plus Bevacizumab Combo in Ovarian CancerПодробнее

Dr. Arend on Unmet Needs in Platinum-Resistant Ovarian CancerПодробнее

The PAOLA-1 study: olaparib and bevacizumab for ovarian cancerПодробнее

Bevacizumab’s Role in Recurrent Ovarian CancerПодробнее

Dr. Arend on Novel Combination Strategies in Gynecologic CancerПодробнее

Niraparib significantly improves outcomes for ovarian cancer patientsПодробнее

Ovarian Cancer: Optimizing Treatment With NiraparibПодробнее

Bevacizumab Ovarian Cancer || Dr. Sarika GuptaПодробнее

Bevacizumab in Recurrent Ovarian CancerПодробнее

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian CancerПодробнее

When to Add Bevacizumab for Recurrent Ovarian CancerПодробнее

PARP + Maintenance Bevacizumab in Ovarian CancerПодробнее